BIOSPAIN 2027 begins to shape the key features of its next edition in Barcelona

Following the conclusion of its latest edition in Bilbao, BIOSPAIN is already preparing for its next event, which will take place in Barcelona (Fira de Barcelona – Montjuïc) from 28 to 30 September 2027. The Spanish Association of Biocompanies (AseBio) and Biocat, the organisation that drives and promotes the life sciences and health innovation ecosystem in Catalonia, known as the Catalonia BioRegion, will organise this new edition in collaboration with the Government of Catalonia and Barcelona City Council.

BIOSPAIN 2027 will once again bring together companies, institutions, research centres, investors and other stakeholders from the national and international biotechnology ecosystem to create new opportunities for collaboration, investment and business, while addressing the main challenges shaping the sector's development. Internationalisation and talent will once again be two of the key pillars of an edition that will take its first steps this November with the opening of exhibition stand sales.

The next edition will build on the success of BIOSPAIN 2026, held in Bilbao from 29 September to 1 October, which brought together more than 1,900 attendees from nearly 900 organisations across 32 countries. The event also welcomed 95 investors from 50 national and international investment organisations and generated more than 4,000 one-to-one meetings over its three days.

Strengthening BIOSPAIN's international dimension

Internationalisation will once again be one of the main pillars of BIOSPAIN 2027. English will remain the official language of the conference, and Mexico will be the Guest Nation at this edition, strengthening opportunities to build new connections and partnerships between the biotechnology ecosystems of Mexico, Spain and Europe.

The organisers will also expand the Connecting Global Partners programme, an initiative designed to connect international delegations with representatives of the Spanish biotechnology ecosystem, enabling them to exchange perspectives, identify new areas of collaboration and strengthen international relationships.

This commitment will help further expand BIOSPAIN's international presence and reinforce its role as a gateway to the Spanish biotechnology ecosystem and a meeting point with other international markets.

Barcelona and Catalonia: a strategic ecosystem for European biotechnology

BIOSPAIN's return to Barcelona following its 2025 edition will bring the event back to one of Europe's most dynamic life sciences and health ecosystems.

According to the 2025 Catalonia BioRegion Report, the ecosystem currently comprises 1,650 companies and 94 research institutions, generates more than 306,000 jobs and accounts for 7.6% of Catalonia's GDP. Its ability to attract investment is also one of its main assets: in 2025, startups and scaleups within the ecosystem achieved a historic record, raising €517 million.

The report also highlights Catalonia's industrial strength: the region accounts for nearly 50% of the turnover of Spain's pharmaceutical industry and is home to 79 manufacturing plants, representing 44% of the national total.

This concentration of scientific, business, clinical and investment capabilities provides a particularly favourable environment for one of BIOSPAIN's main objectives: connecting science, business and investment, and helping turn these connections into new opportunities for collaboration and growth.

Robert Fabregat, Director General of Biocat, states: “The next edition of BIOSPAIN will be a great opportunity to showcase the scientific, business and clinical strength of the BioRegion, and to strengthen the links between research, industry and investment. We are approaching this edition with great enthusiasm and with the aim of making Barcelona and Catalonia a meeting point once again for the national and international biotechnology sectors.”

A platform for the major debates shaping European biotechnology

The BIOSPAIN 2026 programme brought together leading national and European institutional representatives, alongside industry and research leaders, in Bilbao to address some of the main challenges shaping the future of biotechnology. Participants included Juan Cruz Cigudosa, Secretary of State for Science, Innovation and Universities; Javier Padilla, Secretary of State for Health; Raquel Yotti, Commissioner for the PERTE for Advanced Health; Teresa Riesgo, Secretary General for Innovation; and Kristin Schreiber, Director for Chemicals, Bioeconomy and Retail at the European Commission's Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW).

The edition also featured Juan Bueren, Director of the Biomedical Innovation Unit at CIEMAT and a leading expert in gene therapy and advanced therapies, as keynote speaker.

They were joined by other representatives from the European Commission and the Ministries of Health, Science and Industry, who took part in discussions with the biotechnology sector on strategic issues such as the Biotech Act, European competitiveness and strategic autonomy, innovation funding, biomanufacturing, market access and Europe's ability to translate its scientific strengths into business and industrial growth.

BIOSPAIN 2027 will continue this institutional and strategic approach, incorporating into its programme the major debates that will shape the development of biotechnology in Spain and Europe over the coming years.

Talent will once again have its own dedicated space

Alongside internationalisation and the creation of business opportunities, BIOSPAIN 2027 will once again place talent among its priorities with a new edition of Talent Day, which will take place on the final day of the conference.

This initiative aims to bring the professional opportunities offered by biotechnology closer to students, researchers and professionals, while helping companies and organisations in the sector access the specialised talent they need to grow.

The initiative will build on the Talent Day held in Bilbao, which addressed issues such as professional development, the transition from academia to industry, talent attraction and retention, and the diversity of professional profiles required across the biotechnology value chain.

Exhibition stand sales to open in November

The first steps towards shaping BIOSPAIN 2027 will begin in the coming weeks. In November, AseBio will open exhibition stand sales, marking the start of participation for companies and organisations in the exhibition area of the next edition.

Over the coming months, further content, initiatives and programme details for BIOSPAIN 2027 will be announced progressively. The event will once again bring together national and international experts to address the sector's trends and challenges, combining partnering, investor participation, commercial exhibition and various networking opportunities to foster new collaborations.

The official BIOSPAIN 2027 website will be available soon, providing all the information and latest updates about the next edition.